117 related articles for article (PubMed ID: 9459338)
1. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
Modi NB; Eppler S; Breed J; Cannon CP; Braunwald E; Love TW
Thromb Haemost; 1998 Jan; 79(1):134-9. PubMed ID: 9459338
[TBL] [Abstract][Full Text] [Related]
2. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
Cannon CP; McCabe CH; Gibson CM; Ghali M; Sequeira RF; McKendall GR; Breed J; Modi NB; Fox NL; Tracy RP; Love TW; Braunwald E
Circulation; 1997 Jan; 95(2):351-6. PubMed ID: 9008448
[TBL] [Abstract][Full Text] [Related]
3. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Van de Werf F; Barron HV; Armstrong PW; Granger CB; Berioli S; Barbash G; Pehrsson K; Verheugt FW; Meyer J; Betriu A; Califf RM; Li X; Fox NL;
Eur Heart J; 2001 Dec; 22(24):2253-61. PubMed ID: 11728145
[TBL] [Abstract][Full Text] [Related]
5. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
Van de Werf F; Cannon CP; Luyten A; Houbracken K; McCabe CH; Berioli S; Bluhmki E; Sarelin H; Wang-Clow F; Fox NL; Braunwald E
Am Heart J; 1999 May; 137(5):786-91. PubMed ID: 10220625
[TBL] [Abstract][Full Text] [Related]
8. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
[TBL] [Abstract][Full Text] [Related]
9. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.
Wang-Clow F; Fox NL; Cannon CP; Gibson CM; Berioli S; Bluhmki E; Danays T; Braunwald E; Van De Werf F; Stump DC
Am Heart J; 2001 Jan; 141(1):33-40. PubMed ID: 11136484
[TBL] [Abstract][Full Text] [Related]
10. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
Gibson CM; Cannon CP; Murphy SA; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Fox NL; Berioli S; Weaver WD; Van de Werf F; Braunwald E
Am J Cardiol; 1999 Nov; 84(9):976-80. PubMed ID: 10569649
[TBL] [Abstract][Full Text] [Related]
11. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
Al-Shwafi KA; de Meester A; Pirenne B; Col JJ
Am Heart J; 2003 Feb; 145(2):217-25. PubMed ID: 12595837
[TBL] [Abstract][Full Text] [Related]
12. A faster-acting and more potent form of tissue plasminogen activator.
Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
[TBL] [Abstract][Full Text] [Related]
13. [An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction].
Liang F; Wang LZ; Hu DY; Shi XB; Wei JP; Zhao H; Wang L; Jia SQ; Wang HY; Liu RH; Chen YD; Lu YL
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):514-7. PubMed ID: 19927632
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
Kostis JB; Dockens RC; Thadani U; Bethala V; Pepine C; Leimbach W; Vachharajani N; Raymond RH; Stouffer BC; Tay LK; Shyu WC; Liao WC
Clin Pharmacokinet; 2002; 41(6):445-52. PubMed ID: 12074692
[TBL] [Abstract][Full Text] [Related]
15. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
Tanswell P; Modi N; Combs D; Danays T
Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
[TBL] [Abstract][Full Text] [Related]
18. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).
Gibson CM; Marble SJ
Clin Cardiol; 2001 Sep; 24(9):577-84. PubMed ID: 11558838
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial.
Wang HB; Ji P; Zhao XS; Xu H; Yan XY; Yang Q; Yao C; Gao RL; Wu YF; Qiao SB
BMJ Open; 2017 Sep; 7(9):e016838. PubMed ID: 28928186
[TBL] [Abstract][Full Text] [Related]
20. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
Serebruany VL; Malinin AI; Callahan KP; Binbrek A; Van De Werf F; Alexander JH; Granger CB; Gurbel PA;
Am Heart J; 2003 Apr; 145(4):636-42. PubMed ID: 12679759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
